MedPath

Enteral Feeding of Premature Babies and Olive Oil Supplementation

Not Applicable
Recruiting
Conditions
Premature
Enteral Feeding
Olive Oil
Registration Number
NCT06072625
Lead Sponsor
Bursa City Hospital
Brief Summary

It is a two-arm prospective interventional study. 40 babies in both groups will be enrolment in the study. In the intervention group, babies will take 1 ml/kg/day of the study product (ULTRA PREMIUM) after full enteral feeding.

Supplementation will continue until discharge or the 36th week. Blood samples will be taken for serum Total antioxidant capacity and Malondialdehyde levels before the intervention and on the 14th day of the control group. At the end of the study, serum will be taken again for control values.

Daily lipid intake amounts will be recorded through breast milk analysis. Lipid profile will be monitored weekly The growth parameters of babies will be monitored daily It will be evaluated at the end of the study in terms of ROP, BPD, and NEC. At the end of the study, the data of babies in both groups will be compared.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Premature babies born at 32 weeks or less
  • Babies who tolerate full enteral feeding at the before end of the second week
  • Babies given consent by their parents -
Exclusion Criteria
  • Having a congenital or genetic anomaly

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of patients who completed the study15 months

To enrolment of 40 babies in the study in both groups

Postnatal growth retardation rates18 months

Daily weight intake amounts of babies in both groups

Secondary Outcome Measures
NameTimeMethod
Frequency and severity of retinopathy of prematurity18 months

Frequency and severity of retinopathy of prematurity

Trial Locations

Locations (1)

Bursa City Hospital

🇹🇷

Bursa, Turkey

Bursa City Hospital
🇹🇷Bursa, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.